Cotrimoxazole Versus Vancomycin for Invasive Methicillin-resistant Staphylococcus Aureus Infections
Methicillin-resistant Staphylococcus aureus (SA) is a major pathogen causing mainly health-care associated infections and, lately, also community acquired infections. Few treatment choices exist to treat these infections. The currently recommended antibiotics for these infections are glycopeptides (vancomycin or teicoplanin). Glycopeptide treatment hs several disadvantages. It is a last resort antibiotic family that should be reserved for the future; Vancomycin is less effective that beta-lactam drugs for SA infections susceptible to both agents; treatment can only be given intravenously; and use of vancomycin has led to the development of SA strains with partial or complete resistance to vancomycin. Cotrimoxazole is an old antibiotic active against most strains of MRSA, depending on local epidemiology.
Study hypothesis: The purpose of this study is to show that cotrimoxazole is as effective as treatment with vancomycin for invasive MRSA infections.
We plan a randomized controlled trial comparing treatment with cotrimoxazole vs. vancomycin for invasive MRSA infections. The primary efficacy outcome we will assess will be Improvement or cure with or without antibiotic modifications, defined as: survival at 7 days post randomization with resolution of fever (<38 for two consecutive days) and resolution of hypotension (>90 systolic without need for vasopressor support); and physician's assessment that the primary infection was improved or cured. The primary safety outcome will be all-cause 30-day survival.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Treatment With Cotrimoxazole vs. Vancomycin for Infections Caused by Methicillin-resistant Staphylococcus Aureus: Randomized Controlled Trial|
- Primary efficacy: Improved or cure with or without antibiotic modifications, defined as: survival at 7 days post randomization with resolution of fever and resolution of hypotension [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]
- Primary safety: 30-day all cause mortality [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
- Improved or cure without antibiotic modifications [ Time Frame: 7 days ] [ Designated as safety issue: No ]
- Modification of the anti-staphylococcal treatment within 1 week of treatment onset for perceived failure of therapy [ Time Frame: 7 days ] [ Designated as safety issue: No ]
- Survival at 7 days post randomization without the need for modification of the anti-staphylococcal antibiotic [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]
- Bacteriological failure, defined as persistent isolation of Staphylococcus aureus with the same phenotype 7 days after or more after treatment onset [ Time Frame: 7 days ] [ Designated as safety issue: No ]
- Need for surgical intervention or other invasive procedures [ Time Frame: 30 days ] [ Designated as safety issue: No ]
- Need for central catheter removal [ Time Frame: 30 days ] [ Designated as safety issue: No ]
- Persistent bacteremia [ Time Frame: 30 days ] [ Designated as safety issue: No ]
- All-cause mortality in ICU and in-hospital [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
- Adverse events [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
- Durations of fever, assigned antibiotic treatment, mechanical ventilation, ICU and hospital stay [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
- Resistance development [ Time Frame: 30 days ] [ Designated as safety issue: No ]
|Study Start Date:||June 2007|
|Estimated Study Completion Date:||January 2015|
|Estimated Primary Completion Date:||January 2015 (Final data collection date for primary outcome measure)|
Cotrimoxazole arm: intravenous cotrimoxazole 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 12 hours. Patients intolerant of volume overload will be given the same dose in 250ml D5W (as in the current recommendations used in the hospital). The dose was selected basing on the existing randomized controlled trial and a pharmacokinetic study . 21 For patients with GFR< 30 the dosage interval will be increased to 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 24 hours. 22 Patients on peritoneal dialysis will be given 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) Q 48 hours. Patients with acute renal failure treated with hemodialysis will be given the 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) after dialysis. Patients on continuous hemofiltration for acute renal failure will be administered the dose for GFR<30.
Active Comparator: B
intravenous vancomycin 1gr Q 12 hours. Adjustment to creatinine clearance: GFR 10-50 1 gr Q 24-96 hours, GFR <10 1gr Q 4-7 days.
Staphylococcus aureus (SA) is a major pathogen causing community-acquired and health-care associated infections. In hospitals, SA infections are associated with a significant burden; in-hospital mortality during the last 15 years following SA bacteremia in Beilinson hospital was 38% and did not decrease in recent years. Resistance to beta-lactams is widely prevalent in hospitals (57% of all SA isolates causing bacteremia at our center). The drug of choice currently recommended for these infections is a glycopeptide (vancomycin or teicoplanin).
Cotrimoxazole (trimethoprim-sulfamethoxazole) is a relatively 'old' drug commonly used for urinary tract infections. Invitro, it is active against SA, including methicillin-resistance Staphylococcus aureus (MRSA) strains and its activity against SA is bactericidal. Trimethoprim alone is bactericidal against SA, while sulphamethoxazole alone is relatively inactive and their combination is synergistic both in-vitro and invivo. The prevalence of cotrimoxazole-susceptible SA varies locally. At our center, 97% of SA strains causing bacteremia in 2004 were susceptible to cotrimoxazole. Community-acquired MRSA, prevalent in the United States as a cause for severe skin and soft tissue infections, has not been described in Israel.
Several reasons exist to search for antibiotics other than vancomycin for MRSA infections. Vancomycin is less effective that beta-lactam drugs for SA infections susceptible to both agents. It is the last resort antibiotic for MRSA infections out of the currently recommended bactericidal antibiotics for invasive infections. Use of vancomycin has led to the development of SA strains with partial or complete resistance to vancomycin (VISA and VRSA, respectively). Vancomycin use is associated with the appearance of vancomycin-resistant enterococcus (VRE) species. Nosocomial infections with VISA and VRE are difficult to treat and may spread rapidly in the hospital. 10 Finally, vancomycin cannot be administered orally.
Limited evidence supports the efficacy of cotrimoxazole for MRSA infections, with paucity of data for high-burden invasive infections. Cotrimoxazole is probably inferior to vancomycin for methicillin-susceptible SA. ; thus we may infer indirectly its inferiority to methicillin and drugs alike for MRSA infections. Cotrimoxazole may be less effective than glycopeptides and oxacillin for left-sided endocarditis. No evidence exists to support the use of cotrimoxazole empirically for the treatment of suspected SA infections in the hospital.
We plan an open label single-center pragmatic randomized controlled trial to compare cotrimoxazole to vancomycin. We will include patients with documented or highly suspected MRSA infections, according to pre-defined risk factors. We chose to target this patient population to assess the efficacy of cotrimoxazole both empirically and for documented infections.
|Contact: Laura Farbman, MHAfirstname.lastname@example.org|
|Contact: Jihad Bishara, MDemail@example.com|
|Emek Medical Center||Recruiting|
|Contact: R. Raz, Professor 972-4-6494259 firstname.lastname@example.org|
|Contact: Hanna Edelstein 972-4-6494259 email@example.com|
|Principal Investigator: R. Raz, Professor|
|Wolfson Medical Center||Recruiting|
|Contact: Michael Dan, Professor 972-3-5028729 firstname.lastname@example.org|
|Principal Investigator: Michael Dan, Professor|
|Rambam medical centre||Recruiting|
|Contact: Mical Paul, M.D. +97250-2062140 M_Paul@rambam.health.gov.il|
|Principal Investigator: Mical Paul, Professor|
|Rabin Medical Center; Beilinson Hospital and Davidoff Cancer Center||Recruiting|
|Petah Tikva, Israel, 49100|
|Contact: Leonard Leibovici, MD 972-3-9376501 email@example.com|
|Sub-Investigator: Silvio Pitlik, MD|
|Sub-Investigator: Zmira Samra, Prof.|
|Sub-Investigator: Pierre singer, MD|
|Sub-Investigator: Leonard Leibovici, MD|
|Principal Investigator:||Mical Paul, MD||Rabin Medical Center|
|Principal Investigator:||Jihad Bishara, MD||Rabin Medical Center|